Telomir Pharma CFO Nathan Fuentes resigns; Michelle Yanez appointed CFO

Telomir Pharmaceuticals, Inc.

CFO Nathan Fuentes resigned June 18, 2024; separation includes $62,500 over 3 months and option extension.
Michelle Yanez, MBA, appointed CFO effective June 18; was part-time Corporate Controller since May 2022.
Yanez also serves as CFO of MIRA Pharmaceuticals (Nasdaq: MIRA); base salary $137,500/yr.
Yanez receives sign-on bonus tied to change of control, discretionary annual bonus, no upfront equity.
Resignation was not based on any disagreement with Company's operations, policies, or practices.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nathan Fuentes

Chief Financial Officer

TELO · Telomir Pharmaceuticals, Inc.

Effective: 2024-06-18
Successor: Michelle Yanez
Filed: June 24, 2024, 7:59 PM ET

On June 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the “ Separation Agreement ”) whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes’ employment as a Chief Financial Officer of the Company would end as of June 18, 2024.

Appointed

Michelle Yanez

Chief Financial Officer

TELO · Telomir Pharmaceuticals, Inc.

Effective: 2024-06-18
Filed: June 24, 2024, 7:59 PM ET

On June 18, 2024, the Board of the Company appointed Michelle Yanez, MBA as the Chief Financial Officer, of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nathan Fuentes resigned as Chief Financial Officer at Telomir Pharmaceuticals, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On June 18, 2024, Telomir Pharmaceuticals, Inc. (the “ Company ”) and Nathen Fuentes entered into a Confidential Separation and Mutual General Release Agreement (the “ Separation Agreement ”) whereby both the Company and Mr. Fuentes mutually agreed that Mr. Fuentes’ employment as a Chief Financial Officer of the Company would end as of June 18, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Michelle Yanez was appointed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 18, 2024, the Board of the Company appointed Michelle Yanez, MBA as the Chief Financial Officer, of the Company.

View on SEC.gov

Telomir Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-024812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.